| |
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities.
|
|
Today’s Big NewsJul 19, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
| By Angus Liu Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found. |
|
|
|
By Nick Paul Taylor Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap between their positions before tying the knot. |
By Conor Hale As Intuitive Surgical continues to roll out its latest da Vinci robot, following its launch in March, the company warned that supplies may be tight for the next 12 months. |
By Andrea Park As Abbott prepares to enter new territory with the impending U.S. launch of the first version of its continuous glucose monitoring technology designed to be used by people without diabetes, it’s taking a very deliberate approach to marketing the sensor. |
|
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By James Waldron The biotech has knocked its share price down to $12, but raised the number of shares on offer to 13.9 million. |
By Kevin Dunleavy The U.S. government has exercised a contract option and will pay $113 million for delivery of Siga Technologies’ oral smallpox antiviral Tpoxx. |
By James Waldron GRO Biosciences has ended the week with an extra $60.3 million in the bank, which the protein therapeutics-focused biotech will use to push its lead gout treatment into clinical trials. |
By Kevin Dunleavy The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death compared with Fotivda alone in kidney cancer patients who had tried an immune checkpoint inhibitor. |
By Darren Incorvaia A paper published in Nature on July 10 shows that an enzyme from a bacteriophage extended the lives of mice afflicted by aGVHD, suggesting that the protein could have potential as a treatment for allo-HCT patients suffering from it as well. |
Fierce podcastsDon’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
